Two Drugs for Advanced Lung Cancer With KRAS Mutation
Part of Cancer clinical trials.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced (stage IV) non-small cell lung cancer confirmed by biopsy or tissue sample
- Cancer has a KRAS mutation (a specific genetic change)
- You've already received at least one prior treatment (like chemotherapy or immunotherapy) and your cancer got worse
- Good overall health (able to perform daily activities with little or no assistance)
- Expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for lung cancer with a KRAS mutation. The drugs may shrink or slow the cancer, and one of them helps your immune system fight the cancer.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Hear when a new Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.